A Randomized, 3 arm, multicenter Phase III study to Evaluate the Efficacy and the Safety of T-DM1 combinded with Pertuzumab or T-DM1 combined with Pertuzumab-Placebo (blinded for Pertuzumab)vs the combination of Trastuzumab plus Taxane, as first line t
|Effective start/end date||5/19/10 → 6/30/17|
- HOFFMANN-LA ROCHE PHARMACEUTICALS
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.